::: danger URGENT CLINICAL WARNINGS (PROFESSIONAL REFERENCE)
A comprehensive, evidence-ranked clinical manual for diagnosing and managing idiopathic Parkinson's disease, optimizing motor and non-motor symptoms, and executing advanced multi-modal rehabilitation protocols.
Idiopathic Parkinson's disease (PD) is a progressive neurodegenerative disorder primarily characterized by the loss of dopaminergic neurons within the substantia nigra pars compacta, leading to profound striatal dopamine depletion. Beyond classical neurodegeneration, recent translational research highlights that neuroinflammation plays a critical role in disease pathogenesis. Advanced neuroimaging, specifically using diffusion MRI to measure regional free-water diffusion (FWD), serves as a non-invasive biomarker that correlates strongly with plasma glial fibrillary acidic protein (GFAP) concentrations—a key marker of astrogliosis and active neuroinflammation—rather than neurofilament light chain (NfL) measures of axonal damage [14].
This underlying neuroinflammatory cascade and progressive synucleinopathy disrupt motor circuitries (such as the basal ganglia loop) and widespread non-motor pathways, culminating in the heterogeneous clinical phenotype of motor, autonomic, cognitive, and neuropsychiatric disturbances observed across different stages of the disease.
| Intervention | Evidence Level | What to do | Notes & Citations |
|---|---|---|---|
| Levodopa Therapy | High (Gold Standard) | Initiate as first-line treatment for motor symptoms; use lowest effective dose. | Superior motor benefits compared to dopamine agonists [15]; clinical trials show it dose-dependently improves motor function [16]. |
| Physical Exercise (Dance, Gait/Balance) | High | Engage in structured physical exercise for a minimum of 8 weeks and 30 sessions. | Proven to reduce motor severity on UPDRS-III scale and preserve functional mobility [9:1][10:1][11:1][17]. |
| Subthalamic Nucleus DBS (STN-DBS) | High | Refer eligible patients with motor fluctuations refractory to medical therapy. | Highly effective surgical option to reduce motor fluctuations in appropriately selected patients [18]. |
| Sublingual Atropine | Moderate | Administer atropine sublingually for sialorrhea (drooling). | Sublingual route is clinically superior to oral or subcutaneous routes for managing salivary flow [19]. |
| Probiotic Supplements | Moderate | Administer daily probiotic supplements. | Clinically proven to increase complete bowel movements and improve constipation-related quality of life [20]. |
| Clozapine | Moderate | Prescribe low-dose clozapine for refractory hallucinations and psychosis. | Supported by long-term efficacy trials showing clinical benefit [6:2]. |
| Oral Pharmacotherapy | Moderate | Prescribe oral medications for neurogenic bladder symptoms. | Prescribe oral medications for neurogenic bladder symptoms when conservative measures fail [12:1]. |
| Acupuncture | Low | Consider manual acupuncture as an adjunct therapy for comorbid anxiety. | Manual acupuncture combined with routine drug therapy shows mild benefits for anxiety [21]. |
| Nilotinib | Very Low (Incompetent Efficacy) | Do NOT prescribe for motor outcomes. | Shows favorable safety and biomarker changes, but fails to provide clinical motor benefits [22]. |
Establishing an accurate diagnosis of Parkinson's disease (PD) requires strict adherence to the International Parkinson and Movement Disorder Society (MDS) clinical diagnostic criteria [1:3]. The core clinical diagnostic criteria of Parkinson's Disease require the presence of bradykinesia (slowness of movement with progressive decrease in amplitude or speed during repetitive tasks) combined with at least one of the following:
Clinicians must systematically distinguish idiopathic PD from secondary parkinsonism and atypical parkinsonian syndromes, which include Progressive Supranuclear Palsy (PSP), Corticobasal Syndrome/Degeneration (CBS/CBD), Dementia with Lewy Bodies (DLB), and Multiple System Atrophy (MSA) [1:4][7:1], with specific clinical diagnostic criteria for MSA detailed in [8:1].
To ensure diagnostic precision and avoid inappropriate pharmacological intervention, clinicians must conduct a detailed comparative analysis against key mimics:
While structural MRI is routinely performed to exclude secondary causes (such as vascular parkinsonism or normal pressure hydrocephalus), advanced neuroimaging techniques provide key diagnostic utility. Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) is recommended by expert panels as a clinically useful imaging biomarker to discriminate idiopathic PD from atypical parkinsonian syndromes associated with dementia [7:2]. Additionally, diffusion MRI assessing regional free-water diffusion (FWD) offers a non-invasive biomarker of astrogliosis and neuroinflammation, showing strong associations with plasma glial fibrillary acidic protein (GFAP) levels [14:1].
Clinical outcome assessments (COAs) are essential for evaluating symptom severity, treatment response, and disease progression in Parkinson's disease, with priority areas for clinical validation including anxiety, apathy, anhedonia, dysautonomia, and pain [24]. Genetic testing and screening may also be considered in early-onset cases or when familial inheritance is suspected [25].
The clinical management of PD's cardinal motor symptoms—bradykinesia, rigidity (typically presenting as classic cogwheel rigidity), resting tremor (frequently presenting as an asymmetric pill-rolling resting tremor), and postural instability—rests on optimizing dopaminergic neurotransmission. For patients presenting with early-stage disease, clinicians must decide between initiating treatment with levodopa or a dopamine agonist (DA) [26][15:1]. Clinical practice guidelines establish that levodopa provides superior motor symptom benefit and immediate quality-of-life improvements compared to dopamine agonists [15:2]. Levodopa initiation is associated with a higher long-term risk of developing motor fluctuations and dinesia [26:1][15:3], whereas dopamine agonists carry a higher risk of impulse control disorders [15:4]. Prescribing trends in the United Kingdom from 2019 to 2024 confirm that levodopa remains the most widely prescribed first-line agent, although regional prescribing variations persist [27]. The landmark ELLDOPA trial evaluated levodopa in early PD and demonstrated dose-dependent improvements in motor symptoms that persisted even after a two-week washout period, although the results were not conclusive regarding whether levodopa slows or accelerates underlying disease progression [16:1]. No clinical evidence supports initiating therapy with sustained-release levodopa over immediate-release formulations in early-stage disease [26:2][15:5].
For patients experiencing motor fluctuations, adjunctive therapies are indicated. Monoamine omission or delay can precipitate motor fluctuations. Monoamine oxidase B (MAO-B) inhibitors, such as safinamide, and COMT inhibitors are add-on options that are efficacious in reducing daily "off" time and optimizing "on" time [18:1].
Tremor is often perceived as severely disabling by patients and remains one of the most difficult symptoms to manage. A comprehensive meta-analysis of non-lesional tremor treatments demonstrated a large, non-specific benefit across various dopaminergic classes, with subgroup analyses indicating superior tremor reduction with pramipexole and rotigotine compared to ropinirole [28]. Physical therapy interventions, including electrical stimulation, the use of weighted tremor gloves, and eccentric exercises, have also shown localized reductions in tremor amplitude and improvement in resting tremor velocity [29].
Camptocormia—an abnormal forward flexion of the spine that resolves in the recumbent position—is a potentially debilitating motor complication [30]. Systematic reviews indicate that subthalamic nucleus Deep Brain Stimulation (STN-DBS) can correct the sagittal plane imbalance, with a duration of camptocormia of 2 years or less predicting significantly better surgical outcomes (OR 4.15) [30:1]. In contrast, spine surgery corrected spinal imbalance but was associated with a high complication rate [30:2].
Non-motor symptoms represent a major source of disability and impaired quality of life in advanced PD, requiring systematic screening and targeted multidisciplinary management. Autonomic dysfunction—specifically urogenital, sexual, and gastrointestinal impairment—is highly prevalent. Urogenital and sexual symptoms should be managed using evidence-based parameters, such as the European Academy of Neurology (EAN/EFAS/INUS) NEUROGED guidelines [12:2], which cover urogenital symptoms only. The clinical application of these NEUROGED guidelines helps neurologists manage the complexities of neurogenic bladder and sexual dysfunctions in daily practice [31][12:3]. Additionally, non-drug measures, such as exercise, cognitive behavioral therapy, and acupuncture, show significant clinical improvements in sleep, depression, anxiety, and quality of life in patients with PD [32].
Neuropsychiatric symptoms are intrinsically linked to the neurodegenerative process of PD and require precise clinical characterization:
Sleep architecture is profoundly disrupted in PD due to the degeneration of sleep-regulating pathways in the brainstem:
Bladder symptoms can be clinically assessed with urinalysis, bladder diaries, and post-void residual volume measurements [12:4].
Bowel dysmotility and severe constipation are common features of autonomic dysfunction in PD. Systematic reviews and meta-analyses of randomized controlled trials demonstrate that daily supplementation with probiotic supplements significantly improves constipation symptoms [20:1]. Probiotic therapy is associated with a statistically significant increase in the weekly frequency of complete bowel movements (CBMs) and marked improvements in patient-reported quality of life, as measured by the Patient Assessment of Constipation Quality of Life (PAC-QOL) questionnaire [20:2]. Probiotics serve as an important, low-risk adjuvant therapy for autonomic bowel dysfunction [20:3].
Physical rehabilitation is established as a cornerstone of non-pharmacological PD management, serving to slow functional decline, preserve mobility, and improve quality of life [10:2][11:2][35][17:1]. Broadly, all forms of structured exercise (including aerobic training, resistance training, dance, and mind-body exercises) provide significant benefits compared to sedentary care [10:3][11:3][17:2]. Complementary therapies (such as music, dance, and drama) also demonstrate moderate evidence of benefit in improving balance and functional mobility in individuals with PD [36].
Cochrane network meta-analyses of over 150 randomized trials have identified key modal-specific therapeutic advantages [10:4][11:4][17:3]:
Freezing of gait (FOG) is a highly disabling, transient episode of immobility that frequently leads to falls [38][39]. Specialized behavioral training is clinically superior to generic exercises for the long-term management of FOG episodes [39:1].
Recurrent falls are major contributors to morbidity and hospitalization in patients with advanced PD [3:1][4:2][5:1]. Falls are primarily driven by the clinical intersection of progressive postural instability, physical frailty, and neurogenic orthostatic hypotension (nOH) [3:2][4:3].
To mitigate fall risk and optimize safety within the home environment, clinicians must proactively recommend comprehensive environmental modifications:
Neurogenic orthostatic hypotension is a severe autonomic complication that affects cerebral perfusion [3:3]. Delayed orthostatic hypotension (dOH) is twice as frequent in PD as in ageing individuals, mainly driven by progressive orthostatic systolic blood pressure fall [40]. Emerging clinical evidence demonstrates a direct, time-locked correlation between hypotensive episodes and transient cognitive fluctuations (CFs) in patients with Parkinson's disease dementia (PDD) [13:2]. These fluctuations present as acute, caregiver-reported lapses in attention, comprehension, language, and visuospatial orientation [13:3].
Physical frailty is highly prevalent in patients with PD, with a pooled prevalence of 38% using the standard frailty phenotype criteria [4:4]. The presence of frailty is associated with adverse clinical outcomes, including recurrent falls, cognitive impairment, dementia, nursing home placement, and increased in-patient mortality [4:5]. Clinical risk factors correlating with frailty include longer disease duration, advanced motor impairment, a non-tremor dominant phenotype (such as postural instability and gait difficulty [PIGD]), and a higher total daily levodopa dose [4:6]. Early identification of frailty should guide personalized rehabilitative and fall-prevention strategies [4:7].
Bulbar dysfunction, manifesting as dysphagia (swallowing impairment) and sialorrhea (drooling), poses severe clinical risks, including silent aspiration, recurrent aspiration pneumonia, dehydration, and substantial caregiver burden [19:1][2:1].
Neuropsychiatric symptoms, including visual hallucinations, illusions, and paranoid delusions, are common in advanced PD [6:3]. These symptoms are frequently driven by a combination of disease progression and dopaminergic medications [6:4]. Pharmacological strategies for Lewy body dementia and Parkinson's disease dementia should be evaluated carefully, as high-level evidence remains limited [44].
Impulse-Control Disorders (ICDs), including pathological gambling, hypersexuality, compulsive shopping, and binge eating, are severe psychiatric complications of dopaminergic therapy [15:6].
Cognitive and motor impairments associated with progressive PD can significantly compromise driving ability, requiring proactive assessment and clinical counseling [1:7].
Maintaining the strict timing of antiparkinsonian medications during surgical procedures and hospitalizations is a critical clinical priority to prevent severe complications, including akinetic crises and Parkinsonism-Hyperpyrexia Syndrome (PHS) [1:11].
In patients with advanced PD who experience severe motor fluctuations and dyskinesia refractory to oral medication optimization, device-aided advanced therapies must be considered [1:14][46].
Continuous infusion therapies provide stable plasma levodopa concentrations, minimizing the "peaks and troughs" associated with oral dosing [46:1].
Deep Brain Stimulation targeting the subthalamic nucleus (STN) or globus pallidus internus (GPi) is a highly effective, established surgical option for patients with motor fluctuations and refractory tremors [18:2][1:16].
Clinical Efficacy: Clinical guidelines and evidence-based reviews show that bilateral STN-DBS combined with medical therapy is superior to medical therapy alone, resulting in sustained improvements in motor function and quality of life in appropriately selected patients [18:3].
Adaptive DBS (aDBS): This represents an advanced development in neurostimulation [47][48][49][50]. In a blinded randomized feasibility pilot trial of four patients, adaptive DBS was shown to modulate stimulation in real-time based on stimulation-entrained gamma oscillations in the subthalamic nucleus or motor cortex, showing improvements in motor symptoms and quality of life compared to conventional DBS [47:1]. Case reports confirm that adaptive DBS using gamma oscillations can achieve prolonged, stable improvements over conventional DBS for up to eight months [50:1]. The spectral characteristics and performance of subthalamic nucleus beta oscillations as a biomarker are also influenced by active stimulation and medication conditions [49:1].
Disparities in Access: Retrospective clinical cohort analyses reveal significant gender, socioeconomic, and ethnic disparities in DBS referral and implantation [51]. Educated, married, White male patients are statistically overrepresented among those receiving DBS surgery [51:1]. Clinicians must take active steps to ensure equitable screening and referral pathways [51:2].
As PD advances, patients often become homebound and experience complex palliative care needs [52].
Pregnancy in patients with early-onset PD represents a rare but highly complex clinical scenario requiring coordinated, multidisciplinary care [25:1].
For healthcare providers, certain acute presentations in Parkinson's disease require immediate clinical intervention or emergency stabilization:
To explore advanced functional preservation protocols and age-specific conditioning strategies for seniors, refer to the Older Adult Longevity and Functional Preservation Guide. For tracking executive function and memory over time, consult the Cognitive Screening Assessment.
Longevipedia pages are AI-updated and human-reviewed. We prioritize gold-standard systematic reviews, guidelines from major international neurological societies, and registered clinical trials. All statements are backed by peer-reviewed evidence with direct, verified reference links.
Höglinger G, German Parkinson’s Guidelines Committee, Trenkwalder C. Diagnosis and treatment of Parkinson´s disease (guideline of the German Society for Neurology). Neurological Research and Practice. 2024. https://pubmed.ncbi.nlm.nih.gov/38845028/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
George Umemoto, Hitoshi Furuya. Management of Dysphagia in Patients with Parkinson's Disease and Related Disorders. Internal Medicine. 2020. https://pubmed.ncbi.nlm.nih.gov/30996170/ ↩︎ ↩︎ ↩︎ ↩︎
Fanciulli A, Leys F, Falup-Pecurariu C, et al. Management of Orthostatic Hypotension in Parkinson's Disease. Journal of Parkinson's Disease. 2020. https://pubmed.ncbi.nlm.nih.gov/32716319/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
McMillan JM, Michalchuk Q, Goodarzi Z. Frailty in Parkinson's disease: A systematic review and meta-analysis. Clinical Parkinsonism & Related Disorders. 2021. https://pubmed.ncbi.nlm.nih.gov/34316672/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Fanciulli A, Campese N, Goebel G. Association of transient orthostatic hypotension with falls and syncope in patients with Parkinson disease. Neurology. 2020. https://pubmed.ncbi.nlm.nih.gov/32938788/ ↩︎ ↩︎
Eng ML, Welty TE. Management of hallucinations and psychosis in Parkinson's disease. The American Journal of Geriatric Pharmacotherapy. 2010. https://pubmed.ncbi.nlm.nih.gov/20869621/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Walker Z, Gandolfo F, Orini S. Clinical utility of FDG PET in Parkinson's disease and atypical parkinsonism associated with dementia. European Journal of Nuclear Medicine and Molecular Imaging. 2018. https://pubmed.ncbi.nlm.nih.gov/29779045/ ↩︎ ↩︎ ↩︎
Stankovic I, Fanciulli A, Sidoroff V. A Review on the Clinical Diagnosis of Multiple System Atrophy. Cerebellum. 2023. https://pubmed.ncbi.nlm.nih.gov/35986227/ ↩︎ ↩︎ ↩︎ ↩︎
Yang Y, Fu X, Zhang H. The effect of home-based exercise on motor symptoms, quality of life and functional performance in Parkinson's disease: a systematic review and meta-analysis. BMC Geriatrics. 2023. https://pubmed.ncbi.nlm.nih.gov/38114897/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Ernst M, Folkerts AK, Gollan R. Physical exercise for people with Parkinson's disease: a systematic review and network meta-analysis. The Cochrane Database of Systematic Reviews. 2023. https://pubmed.ncbi.nlm.nih.gov/36602886/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Ernst M, Folkerts AK, Gollan R. Physical exercise for people with Parkinson's disease: a systematic review and network meta-analysis. The Cochrane Database of Systematic Reviews. 2024. https://pubmed.ncbi.nlm.nih.gov/38588457/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Panicker JN, Fanciulli A, Skoric MK. European Academy of Neurology (EAN)/European Federation of Autonomic Societies (EFAS)/International Neuro-Urology Society (INUS) Guidelines for Practising Neurologists on the Assessment and Treatment of Neurogenic Urinary and Sexual Symptoms (NEUROGED Guidelines). European Journal of Neurology. 2025. https://pubmed.ncbi.nlm.nih.gov/40208234/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Patino J, Duque K, Abanto J. Hypotensive Episodes Precede Cognitive Fluctuations in Parkinson's Disease Dementia. Movement Disorders Clinical Practice. 2026. https://pubmed.ncbi.nlm.nih.gov/41837340/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Sumra V, Hadian M, Dilliott AA. Regional free-water diffusion is more strongly related to neuroinflammation than neurodegeneration. Journal of Neurology. 2025. https://pubmed.ncbi.nlm.nih.gov/40560468/ ↩︎ ↩︎
Pringsheim T, Day GS, Smith DB. Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee. Neurology. 2021. https://pubmed.ncbi.nlm.nih.gov/34782410/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Fahn S. Levodopa in the treatment of Parkinson's disease. Journal of Neural Transmission. Supplementum. 2006. https://pubmed.ncbi.nlm.nih.gov/17447410/ ↩︎ ↩︎
Cordani C, Mosconi B. What type of physical exercise works best to improve movement and quality of life for people with Parkinson's disease? - A Cochrane Review summary with commentary. NeuroRehabilitation. 2024. https://pubmed.ncbi.nlm.nih.gov/38943407/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
de Bie RMA, Katzenschlager R, Swinnen BEKS, et al. Update on Treatments for Parkinson's Disease Motor Fluctuations - An International Parkinson and Movement Disorder Society Evidence-Based Medicine Review. Movement Disorders. 2025. https://pubmed.ncbi.nlm.nih.gov/40055961/ ↩︎ ↩︎ ↩︎ ↩︎
Yellepeddi VK, Race JA, McFarland MM. Effectiveness of atropine in managing sialorrhea: A systematic review and meta-analysis. International Journal of Clinical Pharmacology and Therapeutics. 2024. https://pubmed.ncbi.nlm.nih.gov/38577753/ ↩︎ ↩︎ ↩︎ ↩︎
Jin X, Dong W, Chang K. Efficacy of probiotic supplements on Parkinson's disease: A systematic review and meta-analysis. Complementary Therapies in Medicine. 2024. https://pubmed.ncbi.nlm.nih.gov/38705493/ ↩︎ ↩︎ ↩︎ ↩︎
Wu Z, Liu C, Chan V. Efficacy of acupuncture in ameliorating anxiety in Parkinson's disease: a systematic review and meta-analysis with trial sequential analysis. Frontiers in Aging Neuroscience. 2024. https://pubmed.ncbi.nlm.nih.gov/39588511/ ↩︎ ↩︎
Xie X, Yuan P, Kou L. Nilotinib in Parkinson's disease: A systematic review and meta-analysis. Frontiers in Aging Neuroscience. 2022. https://pubmed.ncbi.nlm.nih.gov/36248007/ ↩︎
Dash D, Bruno V, Schwingenschuh P, et al. Update on Medical Treatments for Essential Tremor: An International Parkinson and Movement Disorder Society Evidence-Based Medicine Review. Movement Disorders. 2026. https://pubmed.ncbi.nlm.nih.gov/41556478/ ↩︎
Papathoma E, Tsitsi P, Vijiaratnam N. Clinical Outcome Assessments in Parkinson's Disease: A Scoping Review of Current Rating Scales and Future Needs. Movement Disorders Clinical Practice. 2026. https://pubmed.ncbi.nlm.nih.gov/41159296/ ↩︎ ↩︎
Lehn AC, Lee JY, Sciacca G. The Management of Parkinson's Disease Before, during and after Pregnancy-an MDS Scientific Issues Committee Review. Movement Disorders Clinical Practice. 2026. https://pubmed.ncbi.nlm.nih.gov/40832691/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Miyasaki JM, Martin W, Suchowersky O. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review [RETIRED]: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2002. https://pubmed.ncbi.nlm.nih.gov/11781398/ ↩︎ ↩︎ ↩︎
Orayj K. Trends in Parkinson's disease medication prescribing patterns in the UK: An interrupted time series analysis (2019-2024). PLoS One. 2025. https://pubmed.ncbi.nlm.nih.gov/40408537/ ↩︎
Pedrosa AJ, Waldthaler J, Mügge F. Non-lesional treatments for tremor in Parkinson's disease: A systematic review and meta-analysis. European Journal of Neurology. 2023. https://pubmed.ncbi.nlm.nih.gov/37154268/ ↩︎
Shahien M, Elaraby A, Gamal M. Physical therapy interventions for the management of hand tremors in patients with Parkinson's disease: a systematic review. Neurological Sciences. 2023. https://pubmed.ncbi.nlm.nih.gov/36205810/ ↩︎
Chan AK, Chan AY, Lau D. Surgical management of camptocormia in Parkinson's disease: systematic review and meta-analysis. Journal of Neurosurgery. 2019. https://pubmed.ncbi.nlm.nih.gov/30215560/ ↩︎ ↩︎ ↩︎
Adamec I, Krbot Skorić M, Crnošija L. Understanding neurogenic urogenital dysfunction and the clinical application of the EAN/EFAS/INUS NEUROGED guidelines. Autonomic Neuroscience. 2025. https://pubmed.ncbi.nlm.nih.gov/40570806/ ↩︎
Zhang Y, Liu S, Xu K. Non-pharmacological therapies for treating non-motor symptoms in patients with Parkinson's disease: a systematic review and meta-analysis. Frontiers in Aging Neuroscience. 2024. https://pubmed.ncbi.nlm.nih.gov/38737585/ ↩︎ ↩︎
Kwok JYY, Kwan JCY, Auyeung M. Effects of Mindfulness Yoga vs Stretching and Resistance Training Exercises on Anxiety and Depression for People With Parkinson Disease: A Randomized Clinical Trial. JAMA Neurology. 2019. https://pubmed.ncbi.nlm.nih.gov/30958514/ ↩︎ ↩︎ ↩︎
Fanciulli A, Sixel-Döring F, Buhmann C. Diagnosis and treatment of autonomic failure, pain and sleep disturbances in Parkinson's disease: guideline "Parkinson's disease" of the German Society of Neurology. Journal of Neurology. 2025. https://pubmed.ncbi.nlm.nih.gov/39751950/ ↩︎ ↩︎
Okada Y, Ohtsuka H, Kamata N. Effectiveness of Long-Term Physiotherapy in Parkinson's Disease: A Systematic Review and Meta-Analysis. Journal of Parkinson's Disease. 2021. https://pubmed.ncbi.nlm.nih.gov/34366377/ ↩︎ ↩︎
Sabbadin F, Geraci M, Nieddu L. Complementary therapies intervention in Parkinson's disease: systematic review and meta-analysis. Frontiers in Neurology. 2025. https://pubmed.ncbi.nlm.nih.gov/41383242/ ↩︎
Seid AA, Demirdel E, Aychiluhm SB. Multidisciplinary Rehabilitation for People with Parkinson's Disease: A Systematic Review and Meta-Analysis. Parkinson's Disease. 2022. https://pubmed.ncbi.nlm.nih.gov/35265314/ ↩︎ ↩︎ ↩︎ ↩︎
Kwok JYY, Smith R, Chan LML. Managing freezing of gait in Parkinson's disease: a systematic review and network meta-analysis. Journal of Neurology. 2022. https://pubmed.ncbi.nlm.nih.gov/35244766/ ↩︎ ↩︎
Gilat M, Ginis P, Zoetewei D. A systematic review on exercise and training-based interventions for freezing of gait in Parkinson's disease. NPJ Parkinson's Disease. 2021. https://pubmed.ncbi.nlm.nih.gov/34508083/ ↩︎ ↩︎ ↩︎
Calió B, Leys F, Matteucci G. Delayed orthostatic hypotension in Parkinson's disease and in the general ageing population. Age and Ageing. 2025. https://pubmed.ncbi.nlm.nih.gov/40622385/ ↩︎
Fanciulli A, Leys F, Höglinger G. How to treat cardiovascular autonomic failure in Parkinson's disease. Journal of Neural Transmission. 2026. https://pubmed.ncbi.nlm.nih.gov/41484430/ ↩︎ ↩︎ ↩︎
Fanciulli A, Goebel G, Metzler B. Elastic Abdominal Binders Attenuate Orthostatic Hypotension in Parkinson's Disease. Movement Disorders Clinical Practice. 2016. https://pubmed.ncbi.nlm.nih.gov/30363559/ ↩︎
Systematic Review of Behavioral Therapy to Improve Swallowing Functions of Patients With Parkinson's Disease. Journal of Oral Rehabilitation. 2019. https://pubmed.ncbi.nlm.nih.gov/30585913/ ↩︎
Stinton C, McKeith I, Taylor JP. Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis. The American Journal of Psychiatry. 2015. https://pubmed.ncbi.nlm.nih.gov/26085043/ ↩︎
Bittner N, Funk CSM, Schmidt A. Psychiatric Adverse Events of Acetylcholinesterase Inhibitors in Alzheimer's Disease and Parkinson's Dementia: Systematic Review and Meta-Analysis. Drugs & Aging. 2023. https://pubmed.ncbi.nlm.nih.gov/37682445/ ↩︎
Chaudhuri KR, Bergmans B, Freire-Alvarez E. Considerations for Initiation and Maintenance of Foslevodopa/Foscarbidopa for Advanced Parkinson's Disease. Movement Disorders Clinical Practice. 2026. https://pubmed.ncbi.nlm.nih.gov/41540973/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Oehrn CR, Cernera S, Hammer LH, et al. Chronic adaptive deep brain stimulation versus conventional stimulation in Parkinson's disease: a blinded randomized feasibility trial. Nature Medicine. 2024. https://pubmed.ncbi.nlm.nih.gov/39160351/ ↩︎ ↩︎
Leung B, Shcherbakova M, Yao J. Bayesian time-history modeling enhances Parkinsonian motor state classification for adaptive deep brain stimulation. Journal of Neural Engineering. 2026. https://pubmed.ncbi.nlm.nih.gov/42013882/ ↩︎
Hammer LH, Cernera S, Oehrn CR. Stimulation and Medication Effects on Subthalamic Nucleus Beta-Band Power in Parkinson's Disease: Implications for Adaptive Deep Brain Stimulation. Movement Disorders. 2026. https://pubmed.ncbi.nlm.nih.gov/41810591/ ↩︎ ↩︎
Cernera S, Oehrn CR, Hammer LH. Sustained Clinical Benefit of Adaptive Deep Brain Stimulation in Parkinson's Disease Using Gamma Oscillations: A Case Report. Movement Disorders. 2025. https://pubmed.ncbi.nlm.nih.gov/39629629/ ↩︎ ↩︎
Ba F, Poonja S, Torabi P. Ethnic and Gender Disparities in Access to Deep Brain Stimulation Surgery for Parkinson's Disease. Movement Disorders Clinical Practice. 2026. https://pubmed.ncbi.nlm.nih.gov/40904041/ ↩︎ ↩︎ ↩︎
Katz M. Telehealth increases access to palliative care for people with Parkinson's disease and related disorders. Annals of Palliative Medicine. 2020. https://pubmed.ncbi.nlm.nih.gov/31865746/ ↩︎ ↩︎